# GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-glp-drugs-obesity-cancer-insulin.html) · 2026-11-09 · Medicine
Page: https://themorning.science/story/glp-1-drugs-show-lower-obesity-related-cancer-risk-than-insulin-but-not-all-diab-5fb57312b46b5693
Kind: research · Impact: medium

## In brief

- GLP-1 receptor agonists are associated with a lower obesity-related cancer risk than insulin, according to the reported findings.
- The reported difference applies to GLP-1 drugs specifically; not all diabetes treatments show the same lower risk.

## Why it matters

Obesity and type 2 diabetes are linked to several cancers, so the choice of diabetes medication may matter for long-term cancer risk.

## Coverage

- [GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments](https://medicalxpress.com/news/2026-11-glp-drugs-obesity-cancer-insulin.html) — Medical Xpress - latest medical and health news stories, 2026-11-09

Tags: glp-1, obesity, cancer, type 2 diabetes, insulin

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science